Revance and Mylan Provide Updates on Development BOTOX (onabotulinumtoxinA) Biosimilar

Biocon and Mylan’s Ogivri (trastuzumab, biosimilar) Receives Health Canada’s Approval for HER2-Positive Breast and Gastric Cancers
  • Revance to get $25M upfront, milestone payments upon achievement of additional clinical, regulatory and sales targets, plus sales royalties in all relevant markets and will be finalized till Apr 30, 2020
  • In Feb 2018, Revance and Mylan signed global collaboration and license agreement for the development and commercialization of a proposed biosimilar to BOTOX (onabotulinumtoxinA)
  • BOTOX is a neurotoxin therapy injected in the muscles to treat increased muscle stiffness & eye muscle problems (strabismus) or abnormal spasm of the eyelids (blepharospasm)

Click here to read full press release/ article | Ref: Seeking Alpha | Image: Behance